

The ACROSS-China trial

Submission date 05/01/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/05/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 29/05/2008	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Yongjun Wang

Contact details

Beijing Tiantan Hospital
Tiantan Xili 6
Chongwen District
Beijing
China
100050

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ACROSS-protocol 5

Study information

Scientific Title

Abnormal glucose Regulation in patients with acute stroke across China: a national multicentre prospective study

Acronym

ACROSS-China

Study objectives

1. The prevalence of abnormal glucose regulation in patients with acute stroke is high
2. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation
3. Patients with or without abnormal glucose regulation will have different outcomes and recurrent risk of stroke
4. Different subtypes of abnormal glucose regulation have different effects on the outcomes and recurrence of stroke

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Tiantan Hospital Ethics Committee on the 28th August 2007

Study design

Multicentre observational, prospective, cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet.

Health condition(s) or problem(s) studied

Abnormal glucose regulation, acute stroke

Interventions

All participants without a history of diabetes mellitus will be identified as having abnormal glucose regulation or not by using the oral glucose tolerance test (OGTT) three days before discharge. The outcome and recurrence of stroke will be compared between the patients with and without abnormal glucose regulation respectively at three months and one year after the onset of stroke as below:

1. Modified Rankin Scale (mRS)
2. The times of stroke recurrence

The current therapy measures of abnormal glucose regulation in patients with acute stroke will be observed during in-hospital and follow-up.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

The prevalence of abnormal glucose regulation after acute stroke in China, measured by OGTT before discharge.

Secondary outcome measures

1. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation
2. The outcome and recurrence risk of stroke in patients with or without abnormal glucose regulation

Overall study start date

01/01/2008

Completion date

01/09/2008

Eligibility**Key inclusion criteria**

1. Older than 18, either sex
2. Acute stroke: diagnosed on World Health Organization (WHO) criteria
3. Acute primary stroke patients within 14 days

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

4000

Key exclusion criteria

1. Cerebral infarction without symptoms and signs
2. Non-cerebrovascular events
3. Stroke patients out of 14 days
4. Without the content of patients or their legal agents

Date of first enrolment

01/01/2008

Date of final enrolment

01/09/2008

Locations

Countries of recruitment

China

Study participating centre

Beijing Tiantan Hospital

Beijing

China

100050

Sponsor information

Organisation

Bayer (China) Limited

Sponsor details

Corporate Communications

34/F Jing Guang Centre

Hu Jia Lou, Chaoyang District

Beijing

China

100020

Sponsor type

Industry

Website

<http://www.bayerchina.com.cn>

ROR

<https://ror.org/05d5yxq17>

Funder(s)

Funder type

Industry

Funder Name

Bayer (China) Limited

Funder Name

11th Five-year National Supporting Schedule of Science and Technology (China)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration